ABCLAbCellera Biologics Inc.
$12.55+178% 1Y
$12.55
$2.7852 weeks$14.83
ABCL in its own filings
Nothing in ABCL's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
108
Events found in the filings · across 322 filings · the record starts in 2020
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 13, 2026
Most recent filing · Form 8-K
- Record starts
- Nov 2, 2020
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 5, 2026
- Change in certifying accountantpast_year
- 2025-11-28
- SEC comment-letter activity13 occurrences
- 2022-07-28
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 13, 2026On August 12, 2026, AbCellera Biologics Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and J.P. Morgan Securities LLC as the representatives of the several underwriters (the “Underwriters”) relating to an underwritten public offering of (a) 17,435,897 …Material agreement entered · Form 8-K
- Aug 7, 2026On August 7, 2026, AbCellera Biologics Inc. (the “Company”) issued a press release announcing it will release top-line data from its Phase 2 trial evaluating ABCL635 for the treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause on Monday, August 10, 2026 and hold an investor conference call at 4:30 …Other event · Form 8-K
- Jul 29, 2026On July 29, 2026, AbCellera Biologics Inc. (the “Company”) issued a press release announcing a collaboration with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions.Other event · Form 8-K
- Jul 6, 2026Appointment of Director On June 30, 2026, the Board of Directors (the "Board") of AbCellera Biologics Inc. (the "Company") appointed Lynn Seely, M.D as a new Class III director.Director or officer change · Form 8-K
- Jun 17, 2026On June 17, 2026, AbCellera Biologics Inc. (the “Company”) issued a press release announcing a preclinical research collaboration, option and license agreement to discover and develop next-generation T-cell engaging (TCE) multispecific antibodies.Other event · Form 8-K
- Jun 5, 2026Appointment of Director On June 1, 2026, the Board of Directors (the "Board") of AbCellera Biologics Inc. (the "Company") appointed Victor Sandor as a new director.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…